Fusion Antibodies PLC

Fusion Antibodies PLC is a Northern Ireland-based contract research organization (CRO) that provides specialized services for the discovery, engineering, and supply of therapeutic and diagnostic antibodies. The company operates as an extension of its clients' teams, supporting projects from initial antigen design through to cell line development. Its proprietary technology platforms—such as CDRx for antibody humanization and RAMP for affinity maturation—are designed to optimize the performance, manufacturability, and developability of antibodies at a molecular level. The company also offers mammalian protein production services and has expanded into artificial intelligence-driven antibody discovery technologies to maintain a competitive edge in the biotechnology sector.

By helping clients navigate the complex pre-clinical stages of development, Fusion Antibodies enables pharmaceutical, biotech, and life science companies to streamline the progression of clinical candidates. Their work is essential for developing high-quality, high-expressing cell lines that meet cGMP standards, ultimately aiming to reduce the costs and timelines associated with drug development. The firm, founded in 2001 and publicly traded on the London Stock Exchange, works with a diverse range of collaborators to move projects into clinical trials, providing expertise that spans human and veterinary therapeutics as well as diagnostic applications.